Regulatory alerts NICE guidelines

Cancer, Oncology, Haematological malignancies, Oncology Room

Venetoclax in combination recommended for chronic lymphocytic leukaemia

Venetoclax plus obinutuzumab is recommended as an option for untreated chronic lymphocytic leukaemia in final NICE guidance.

Editorial team, Wilmington Healthcare

Published Dec 09, 2020

Join OnMedica and benefit from:

Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
High-quality, evidence-based content developed by expert editors and clinicians
Articles, quizzes, videos, visual summaries and more
Regulatory alerts and round-up of medical journals
New content added daily, so you know you’re always up to date

Existing members Sign in